• Innovation
    • Areas of Focus
    • Technology
    • Product Pipeline
    • Clinical Trials
  • Community
    • Clinical Trials
    • Expanded Access Policy
    • ESG
  • Leadership
    • Executive Team
    • Board of Directors
  • Investors
    • Press Releases
    • Corporate Presentation
    • Events & Presentations
    • Stock Info
    • Analyst Coverage
    • Financials
    • Governance
    • Investor Email Alerts
    • Investor Contacts
  • News
  • Careers
    • Culture & Values
    • Join Our Team
  • Contact
    • Locations
Protagonist Logo. Click to navigate to a home page
Protagonist Logo. Click to navigate to a home page
  • Innovation
    • Areas of Focus
    • Technology
    • Product Pipeline
    • Clinical Trials
  • Community
    • Clinical Trials
    • Expanded Access Policy
    • ESG
  • Leadership
    • Executive Team
    • Board of Directors
  • Investors
    • Press Releases
    • Corporate Presentation
    • Events & Presentations
    • Stock Info
    • Analyst Coverage
    • Financials
    • Governance
    • Investor Email Alerts
    • Investor Contacts
  • News
  • Careers
    • Culture & Values
    • Join Our Team
  • Contact
    • Locations

LATEST NEWS, PUBLICATIONS & EVENTS

An advertisement for rusfertide @ asco 2025 in chicago

Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

May 1, 2025
June 1, 2025
A poster that says fast company we made the list most innovative companies 2025

Protagonist Therapeutics Is One of Fast Company’s Most Innovative Companies of 2025

March 18, 2025
March 18, 2025

J&J and Protagonist Announce Phase 3 Trial Results for icotrokinra (JNJ-2113, formerly PN-235)

November 25, 2024
November 19, 2024

FEATURED STORIES


Three test tubes are sitting in a blue rack in a laboratory.

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor

November 18, 2024
NEWS
Video preview

Polycythemia Vera: Mechanism of Disease

February 21, 2023
WATCH VIDEO
Magazine preview

Cancer Moonshot: How We’re Helping Patients

February 14, 2023
NEWS

RECENT PUBLICATIONS


ASH REVIVE Final Analysis Poster

December 10, 2024
December 10, 2024

Summary of Malignancies Observed Across 5 Phase 2 Open Label Clinical Trials of the Hepcidin Mimetic Rusfertide

November 2, 2023

Oral IL 23 Receptor Peptide Antagonist JNJ 2113: The Journey from De Novo Discovery to Phase 3 Clinical Development Program

October 23, 2023
SEE ALL PUBLICATIONS

Contact Us

+1 (510) 474-0170

[email protected]

Stay Connected

Innovation

Community

Leadership

Investors

News

Careers

Get Our News And Updates Delivered To Your Inbox:

Privacy Policy | Terms of Use | © 2025 Protagonist Therapeutics Inc. All Rights Reserved.

Share by:
×

Health Equity: Improving Access to Medicines, Ensuring Diverse Representation

Spotlight, Arturo Molina, MD, Chief Medical Officer

Dr. Molina, how are you helping to advance access to medicines?

At Protagonist, we work hard to meet the needs of the patient communities who are relying on us to innovate new and better medicines. Part of our commitment to them includes working to advance our medicines through clinical studies as quickly as possible and ensuring patients can access investigational therapies outside of our clinical trials, which has allowed some patients in critical need to access our therapies for several additional years after trials conclude.

We’re seeing a greater push for better representation in therapeutic innovation across the industry. How is Protagonist supporting diverse and equitable discovery and development?

Protagonist actively works to ensure we have strong patient representation in our clinical studies. We actively seek patients from across urban, suburban, and rural locations, from varying age groups and from among diverse backgrounds to ensure equitable patient representation in our study data.

We’re particularly concerned aging populations are left out of clinical studies, and we’re currently working to recruit older patients into our trials.

×

Protagonist: Inclusion by the Numbers

Spotlight: Carena Spivey, Head of HR

Carena, equality, inclusion, and workplace diversity have long been in focus at Protagonist, as expressed through various programs and initiatives. Can you tell us about your approach?

We view our diverse and welcoming corporate culture as being critical to our long-term success – It’s essential to the way we innovate. And we regularly track and report our progress, because we believe that what doesn’t get measured doesn’t get done.
Today:
- 65% of employees are members of underrepresented ethnic communities
- 51% are women
- nearly 50% of our Board identifies as a member of an underserved community or as female

What are you doing to help create a more diverse employee community?

We create the conditions for our employees to thrive, facilitating their learning and growth through a richly supportive workplace setting.

Part of that is creating a speak-up culture; we have cultivated an environment where every voice is heard, and we encourage the expression of different points of view in decision-making processes. At every turn, we encourage deep listening, thoughtful consideration, and open-mindedness that allows for decisions to be changed or refined in step with new data. By embracing our team members’ differences, we create wins for our organization and for patients.